Compare UiPath Inc (PATH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Sana Biotechnology Inc — how do they compare? UiPath Inc trades at $13.49 (market cap $6.91B), while Sana Biotechnology Inc trades at $2.83 (market cap $836.71M). The key difference: UiPath Inc is far larger — about 8.3× Sana Biotechnology Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Sana Biotechnology Inc for 23 Days on average.
| PATH | SANA | |
|---|---|---|
Market Cap | $6.91B | $836.71M |
Volume | 34,321,250 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $19.29 | $5.92 |
52-Week Low | $9.38 | $2.68 |
Typical Hold Time | 139 Days | 23 Days |
Enterprise Value | $5.70B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.
PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
